Clinical trial
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic…
NCT00088998 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00088998 |
|---|---|
| Title | Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, capecitabine, docetaxel |
| Enrollment | 46 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Dec 1, 2010 |
| First posted | Aug 5, 2004 |
| Last update posted | Dec 7, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: